What is the risk of using inhaled long-acting beta-agonists (LABA) for COPD in patients with heart failure with reduced ejection fraction (HFrEF)?
Abstract
LABAs, while effective for managing COPD symptoms, may heighten cardiac failure risk in patients, especially those with cardiovascular comorbidities such as HFrEF.
Fields of Study & Subjects
Chronic Obstructive Pulmonary Disease (COPD) Research
Heart Failure Treatment and Management
Cardiovascular and exercise physiology
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 4 January 2026